Therasense Stock Performance
| THER Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Therasense are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Therasense has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical and fundamental indicators, Therasense is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Quick Ratio | 0.13 | |
| Fifty Two Week Low | 0.0028 | |
| Fifty Two Week High | 2.9200 |
Therasense |
Therasense Relative Risk vs. Return Landscape
If you would invest 0.01 in Therasense on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Therasense or generate 0.0% return on investment over 90 days. Therasense is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Therasense, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Therasense Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Therasense's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Therasense, and traders can use it to determine the average amount a Therasense's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| THER |
Based on monthly moving average Therasense is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Therasense by adding Therasense to a well-diversified portfolio.
Therasense Fundamentals Growth
Therasense Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Therasense, and Therasense fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Therasense Pink Sheet performance.
| Return On Asset | -169.9 | |||
| Current Valuation | 27.3 M | |||
| Shares Outstanding | 6.15 B | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 57.46 X | |||
| Revenue | 353.26 K | |||
| EBITDA | (5.53 M) | |||
| Cash And Equivalents | 127.82 K | |||
| Total Debt | 2.9 M | |||
| Cash Flow From Operations | (5.54 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 52 M | |||
| Retained Earnings | (248.68 M) | |||
| Current Asset | 18.12 M | |||
| Current Liabilities | 11.29 M | |||
About Therasense Performance
Assessing Therasense's fundamental ratios provides investors with valuable insights into Therasense's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Therasense is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.Things to note about Therasense performance evaluation
Checking the ongoing alerts about Therasense for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Therasense help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Therasense generated a negative expected return over the last 90 days | |
| Therasense has some characteristics of a very speculative penny stock | |
| Therasense has a very high chance of going through financial distress in the upcoming years | |
| Therasense currently holds 2.9 M in liabilities. Therasense has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Therasense until it has trouble settling it off, either with new capital or with free cash flow. So, Therasense's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Therasense sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Therasense to invest in growth at high rates of return. When we think about Therasense's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 353.26 K. Net Loss for the year was (7.75 M) with profit before overhead, payroll, taxes, and interest of 256.68 K. | |
| Therasense currently holds about 127.82 K in cash with (5.54 M) of positive cash flow from operations. | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Therasense's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Therasense's stock is overvalued or undervalued compared to its peers.
- Examining Therasense's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Therasense's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Therasense's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Therasense's pink sheet. These opinions can provide insight into Therasense's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Therasense Pink Sheet Analysis
When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.